How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

24,913 results for

Bleeding Disorder

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders. (PubMed)

Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders. Congenital bleeding disorders can cause obstetric haemorrhage during pregnancy, labour and following delivery. Desmopressin acetate (DDAVP) is found to be an effective drug which can reduce the risk of haemorrhage and can also stop bleeding in certain congenital bleeding disorders. Its use in pregnancy has been controversial. Hence beneficial and adverse effects (...) of DDAVP in these groups of pregnant women should be evaluated.This is an update of a Cochrane Review first published in 2013 and updated in 2015.To evaluate the efficacy and safety of DDAVP in preventing and treating acute bleeding in pregnant women with bleeding disorders.We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Coaguopathies Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant and abstract books

2019 Cochrane

2. Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding

Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding - ACOG Menu ▼ Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding Page Navigation ▼ Number 785 Committee on Adolescent Health Care This Committee Opinion was developed by the American College of Obstetricians and Gynecologists’ Committee on Adolescent Health Care (...) in collaboration with committee members Oluyemisi Adeyemi-Fowode, MD and Judith Simms-Cendan, MD. Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding ABSTRACT : Heavy menstrual bleeding is defined as excessive menstrual blood loss that interferes with a woman's physical, social, emotional, or material quality of life. If obstetrician–gynecologists suspect that a patient has a bleeding disorder, they should work in coordination with a hematologist for laboratory

2019 American College of Obstetricians and Gynecologists

3. Gynaecological and Obstetric Management of Women With Inherited Bleeding Disorders

Gynaecological and Obstetric Management of Women With Inherited Bleeding Disorders No. 163-Gynaecological and Obstetric Management of Women With Inherited Bleeding Disorders - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 40, Issue 2, Pages e91–e103 No. 163-Gynaecological and Obstetric Management of Women With Inherited Bleeding Disorders x Christine Demers , MD Québec City, QC x Christine Derzko , MD Toronto, ON x (...) Michele David , MD Montréal, QC x Joanne Douglas , MD Vancouver, BC No. 163, July 2005 (Reaffirmed February 2018) DOI: To view the full text, please login as a subscribed user or . Click to view the full text on ScienceDirect. Figures Figure 1 Establishing a diagnosis of menorrhagia. (Table inspired by JM Higham et al. Br J Obstet Gynaecol 1990;97:734–9) Abstract Objective The prevalence of bleeding disorders, notably von Willebrand disease (vWD), among adult women with objectively documented

2018 Society of Obstetricians and Gynaecologists of Canada

4. Recommendations for the clinical interpretation of genetic variants and presentation of results to patients with inherited bleeding disorders

Recommendations for the clinical interpretation of genetic variants and presentation of results to patients with inherited bleeding disorders 116 | wileyonlinelibrary.com/journal/hae Haemophilia. 2019;25:116–126. © 2019 John Wiley & Sons Ltd 1 | INTRODUC TION Genetic diagnosis for patients with haemophilia has been a routine part of clinical practice in the United Kingdom for two decades. For patients with other inherited bleeding disorders, testing has previ- ously been variably implemented (...) because of reduced availability. This has changed in the last few years with the incorporation of next-generation sequencing (NGS) technology into clinical care for patients with bleeding disorders. Currently, genetic diagnosis can be offered to all patients in the United Kingdom with a bleeding disor- der for which the genetic basis is known. Even in those disorders that are suspected to be inherited but for which the genes responsible have not yet been identified, testing has been offered through

2019 United Kingdom Haemophilia Centre Doctors' Organisation

5. Maternal and foetal outcomes following natural vaginal versus caesarean section (c-section) delivery in women with bleeding disorders and carriers. (Full text)

Maternal and foetal outcomes following natural vaginal versus caesarean section (c-section) delivery in women with bleeding disorders and carriers. Bleeding disorders are uncommon but may pose significant bleeding complications during pregnancy, labour and following delivery for both the woman and the foetus. While many bleeding disorders in women tend to improve in pregnancy, thus decreasing the haemorrhagic risk to the mother at the time of delivery, some do not correct or return quite (...) quickly to their pre-pregnancy levels in the postpartum period. Therefore, specific measures to prevent maternal bleeding and foetal complications during childbirth, are required. The safest method of delivery to reduce morbidity and mortality in these women is controversial. This is an update of a previously published review.To assess the optimal mode of delivery in women with, or carriers of, bleeding disorders.We searched the Cochrane Cystic Fibrosis and Genetic Disorders Coagulopathies Trials

2017 Cochrane PubMed

6. Management of Inherited Bleeding Disorders in Pregnancy (Full text)

Management of Inherited Bleeding Disorders in Pregnancy Management of Inherited Bleeding Disorders in Pregnancy - 2017 - BJOG: An International Journal of Obstetrics & Gynaecology - Wiley Online Library

2017 Royal College of Obstetricians and Gynaecologists PubMed

7. Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders. (Full text)

Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders. Congenital bleeding disorders can cause obstetric haemorrhage during pregnancy, labour and following delivery. Desmopressin acetate is found to be an effective drug which can reduce the risk of haemorrhage and can also stop bleeding in certain congenital bleeding disorders. Its use in pregnancy has been controversial. Hence beneficial and adverse effects (...) of desmopressin acetate in these groups of pregnant women should be evaluated.This is an update of a Cochrane review first published in 2013.To determine the efficacy of desmopressin acetate in preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders.We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Coaguopathies Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant

2015 Cochrane PubMed

8. Non-surgical interventions for treating heavy menstrual bleeding (menorrhagia) in women with bleeding disorders. (Full text)

Non-surgical interventions for treating heavy menstrual bleeding (menorrhagia) in women with bleeding disorders. Heavy menstrual bleeding without an organic lesion is mainly due to an imbalance of the various hormones which have a regulatory effect on the menstrual cycle. Another cause of heavy menstrual bleeding with no pelvic pathology, is the presence of an acquired or inherited bleeding disorder. The haemostatic system has a central role in controlling the amount and the duration (...) of menstrual bleeding, thus abnormally prolonged or profuse bleeding does occur in most women affected by bleeding disorders. Whereas irregular, pre-menarchal or post-menopausal uterine bleeding is unusual in inherited or acquired haemorrhagic disorders, severe acute bleeding and heavy menstrual bleeding at menarche and chronic heavy menstrual bleeding during the entire reproductive life are common.To determine the efficacy and safety of non-surgical interventions versus each other, placebo or no treatment

2014 Cochrane PubMed

9. Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders. (Full text)

Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders. People with haematological disorders are frequently at risk of severe or life-threatening bleeding as a result of thrombocytopenia (reduced platelet count). This is despite the routine use of prophylactic platelet transfusions to prevent bleeding once the platelet count falls below a certain threshold. Platelet transfusions are not without risk and adverse events may be life-threatening (...) Library 2016, Issue 3), MEDLINE (from 1946), Embase (from 1974), CINAHL (from 1937), the Transfusion Evidence Library (from 1950) and ongoing trial databases to 07 March 2016.We included RCTs involving participants with haematological disorders, who would routinely require prophylactic platelet transfusions to prevent bleeding. We only included trials involving the use of the lysine analogues TXA and EACA.Two review authors independently screened all electronically-derived citations and abstracts

2016 Cochrane PubMed

10. MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Other Bleeding Disorders

MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Other Bleeding Disorders MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Other Bleeding Disorders | National Hemophilia Foundation Secondary menu Search form Search this site Search Main menu » » » » MASAC Recommendations Concerning Products Licensed For The Treatment of Hemophilia and Other Bleeding Disorders PrintFriendly MASAC Recommendations Concerning Products (...) Licensed for the Treatment of Hemophilia and Other Bleeding Disorders Date: April 23, 2018 ID: 253 Revisions: 250; 249; 246; 240; 237; 235; 225; 218; 215; 210; 205; 202; 195; 190; 187; 182; 177 Attachment Size 173.75 KB 254.93 KB Recommendations for Physicians Treating Patients with Hemophilia A and B, von Willebrand Disease, and other Congenital Bleeding Disorders: A. Treatment of Hemophilia A 1. Recombinant Factor VIII Concentrates Recombinant (r) FVIII is often produced by two well-established

2017 National Hemophilia Foundation

11. MASAC Guidelines for Perinatal Management of Women with Bleeding Disorders and Carriers of Hemophilia A and B

MASAC Guidelines for Perinatal Management of Women with Bleeding Disorders and Carriers of Hemophilia A and B MASAC Guidelines for Perinatal Management of Women with Bleeding Disorders and Carriers of Hemophilia A and B | National Hemophilia Foundation Secondary menu Search form Search this site Search Main menu » » » » MASAC Guidelines For Perinatal Management of Women With Bleeding Disorders and Carriers of Hemophilia A and B PrintFriendly MASAC Guidelines for Perinatal Management of Women (...) with Bleeding Disorders and Carriers of Hemophilia A and B Date: September 17, 2017 ID: 251 Revisions: 192 Attachment Size 132.39 KB MASAC Document # 251 Replaces Document #192 MASAC GUIDELINES FOR PERINATAL MANAGEMENT OF WOMEN WITH BLEEDING DISORDERS AND CARRIERS OF HEMOPHILIA A OR B The document was approved by the Medical and Scientific Advisory Council (MASAC) of the National Hemophilia Foundation (NHF) on August 26, 2017, and adopted by the NHF Board of Directors on September 17, 2017. Bleeding

2017 National Hemophilia Foundation

12. Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders. (PubMed)

Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders. Congenital bleeding disorders can cause obstetric haemorrhage during pregnancy, labour and following delivery. Desmopressin acetate is found to be an effective drug which can reduce the risk of haemorrhage and can also stop bleeding in certain congenital bleeding disorders. Its use in pregnancy has been controversial. Hence beneficial and adverse effects (...) of desmopressin acetate in these groups of pregnant women should be evaluated.To determine the efficacy of desmopressin acetate in preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders.We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Coaguopathies Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant and abstract books of conferences proceedings. We also searched for any

2013 Cochrane

13. Emicizumab for routine prophylaxis, to prevent bleeding or reduce frequency of bleeding episodes in patients with haemophilia A (congenital factor VIII deficiency), with factor VIII inhibitors

with inhibitors to factor VIII – the Australian Bleeding Disorders Registry indicates that the intended eligible population would be 61 individuals. MSAC noted that a further application for patients who do not have factor VIII inhibitors is anticipated in the future. MSAC considered the comparators – BPA prophylaxis plus on-demand BPAs, or no prophylaxis plus on-demand BPAs – to be appropriate. MSAC noted that both emicizumab and BPA prophylaxis are associated with thromboembolic and bleeding adverse events (...) be managed in the context of Australia’s well-established systems for people with bleeding disorders. 15. Other significant factors Nil 16. Applicant’s comments on MSAC’s Public Summary Document Roche is disappointed by MSAC's recommendation, particularly since PASC proposed in the ratified PICO Confirmation that emicizumab's cost-effectiveness be determined in a cost- utility analysis versus bypassing agents. Despite recognising that access to emicizumab will offer superior health outcomes for patients

2018 Medical Services Advisory Committee

14. Preventing bleeding in patients with congenital bleeding disorders having dental surgery

Preventing bleeding in patients with congenital bleeding disorders having dental surgery Congenital bleeding disorders and dental surgery Search National Elf Service Search National Elf Service » » » » Preventing bleeding in patients with congenital bleeding disorders having dental surgery Jan 8 2016 Posted by Minor oral surgery including dental extraction is very commonly performed. Prolonged bleeding is an occasional complication but it can be serious for those with inherited bleeding (...) disorders , haemophilia or Von Willebrand disease (VWD). The aim of this review was to assess the efficacy of antifibrinolytic agents to prevent bleeding complications in people with haemophilia or VWD undergoing oral or dental procedures. Methods Searches were conducted in the Cystic Fibrosis and Genetic Disorders (CFGD) Trials Register Medline, Embase, Cochrane Library, CINHAL, ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP). Randomised and quasi-randomised

2016 The Dental Elf

15. MASAC Recommendations Regarding Girls and Women with Inherited Bleeding Disorders

MASAC Recommendations Regarding Girls and Women with Inherited Bleeding Disorders MASAC Recommendations Regarding Girls and Women with Inherited Bleeding Disorders | National Hemophilia Foundation Secondary menu Search form Search this site Search Main menu » » » » MASAC Recommendations Regarding Girls and Women With Inherited Bleeding Disorders PrintFriendly MASAC Recommendations Regarding Girls and Women with Inherited Bleeding Disorders Date: November 3, 2016 ID: 245 Revisions: 185; 172; 197 (...) Attachment Size 217.89 KB Inherited bleeding disorders are under-recognized as causes of bleeding in girls and women. However, recent data have documented that 50% of girls and women who are carriers for hemophilia A or B have factor VIII or IX levels below 50%, putting them in the category of mild hemophilia and causing them to have an increased risk of bleeding, especially during menstruation and at the time of an accident, surgery, or delivery. Moreover, up to 1% of all girls and women may have

2016 National Hemophilia Foundation

16. Differences in bleeding phenotype and provider interventions in postmenarchal adolescents when compared to adult women with bleeding disorders and heavy menstrual bleeding (Full text)

Differences in bleeding phenotype and provider interventions in postmenarchal adolescents when compared to adult women with bleeding disorders and heavy menstrual bleeding Due to lack of patient/health care provider awareness causing delayed diagnosis, the bleeding phenotype and provider interventions in adolescents with heavy menstrual bleeding (HMB) and bleeding disorders (BD) may be different when compared to adults.The aim of this study was to compare/characterize bleeding phenotype (...) and logistic regression analyses were performed.Of 269 females (79 adolescents; median age 16 years, interquartile range (IQR) = 2; 190 adults; median age 27 years, IQR = 13) evaluated, BD distribution was similar in both groups. Compared to adolescents, adults more often had family history of bleeding (Adjusted odds ratios [AOR] = 2.6, 1.3-5.6), delay in diagnosis (AOR = 2.5, 1.2-4.9), bleeding with dental procedures (AOR = 2.0, 1.0-4.0), gastrointestinal bleeding (AOR = 4.6, 1.0-21.9), anaemia (AOR = 2.7

2017 Haemophilia : the official journal of the World Federation of Hemophilia PubMed

17. Maternal and foetal outcomes following natural vaginal versus caesarean section (c-section) delivery in women with bleeding disorders and carriers. (Full text)

Maternal and foetal outcomes following natural vaginal versus caesarean section (c-section) delivery in women with bleeding disorders and carriers. Bleeding disorders are uncommon but may pose significant bleeding complications during pregnancy, labour and following delivery for both the woman and the foetus. While many bleeding disorders in women tend to improve in pregnancy, thus decreasing the haemorrhagic risk to the mother at the time of delivery, some do not correct or return quite (...) quickly to their pre-pregnancy levels in the postpartum period. Therefore, specific measures to prevent maternal bleeding and foetal complications during childbirth, are required. The safest method of delivery to reduce morbidity and mortality in these women is controversial.To assess the optimal mode of delivery in women with, or carriers of, bleeding disorders.We searched the Cochrane Cystic Fibrosis and Genetic Disorders Coagulopathies Trials Register, compiled from electronic database searches

2015 Cochrane PubMed

18. A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. (Full text)

A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. Platelet transfusions are used in modern clinical practice to prevent and treat bleeding in thrombocytopenic patients with bone marrow failure. Although considerable advances have been made in platelet transfusion therapy in the last 40 years, some areas continue to provoke debate, especially (...) at these questions individually; this review is the first part of the original review.To determine whether a therapeutic-only platelet transfusion policy (platelet transfusions given when patient bleeds) is as effective and safe as a prophylactic platelet transfusion policy (platelet transfusions given to prevent bleeding, usually when the platelet count falls below a given trigger level) in patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation.We searched

2015 Cochrane PubMed

19. Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. (Full text)

Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. Platelet transfusions are used in modern clinical practice to prevent and treat bleeding in people who are thrombocytopenic due to bone marrow failure. Although considerable advances have been made in platelet transfusion therapy in the last 40 years, some (...) . This review has now been split into four smaller reviews looking at these questions individually; this review compares prophylactic platelet transfusion thresholds.To determine whether different platelet transfusion thresholds for administration of prophylactic platelet transfusions (platelet transfusions given to prevent bleeding) affect the efficacy and safety of prophylactic platelet transfusions in preventing bleeding in people with haematological disorders undergoing myelosuppressive chemotherapy

2015 Cochrane PubMed

20. Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. (Full text)

Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. Platelet transfusions are used in modern clinical practice to prevent and treat bleeding in people who are thrombocytopenic due to bone marrow failure. Although considerable advances have been made in platelet transfusion therapy in the last 40 years, some areas continue to provoke debate, especially concerning (...) compares different platelet transfusion doses.To determine whether different doses of prophylactic platelet transfusions (platelet transfusions given to prevent bleeding) affect their efficacy and safety in preventing bleeding in people with haematological disorders undergoing myelosuppressive chemotherapy with or without haematopoietic stem cell transplantation (HSCT).We searched for randomised controlled trials in the Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Library 2015

2015 Cochrane PubMed

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>